INHIBIKASE THERAPEUTICS, INC. (IKT) valuation
Share price $1.68 · As of last filing 2026-03-31
Special situation detected — historical normalisation may not reflect go-forward economics.
EPV and Reverse-DCF outputs below are anchored on history that
no longer represents the entity going forward
(net cash > 50% of market cap)
.
Inspect the balance sheet, recent 8-K filings, and the cards
above before relying on these models.
- net cash > 50% of market cap. Net cash $170.3M (cash $170.4M − debt $110517) = 76.8% of market cap $221.8M